The company has acquired Disperzyme, Disperzyme-CD and Phlogam as part of the deal.

Acquired from Aksigen Hospital, Disperzyme, Disperzyme-CD and Phlogam have been approved by the Drugs Controller General of India for post-operative inflammation in patients undergoing minor surgery and dental procedures

​Nifty has broken down from its consolidation range and slipped below its 100-day exponential moving average (EMA) of 17,900 levels, which was being defended for the past 23 sessions. The short-term moving averages are in a falling mode, which indicates the bearish momentum could continue in the upcoming week.

Higher contribution from specialty and strong domestic franchise is likely to change the product mix towards more remunerative businesses by FY23.

SEZABY is the first and only product approved by the US Food and Drug Administration (USFDA) for the treatment of neonatal seizures in term and preterm infants, Sun Pharma said in a regulatory filing.

Brokers remain positive about the acquisition and believe in the growth potential of Deuroxolitinib, which is a part of Concert's patent portfolio

Concert's lead candidate, deuruxolitinib, is being evaluated as a treatment for autoimmune condition alopecia areata, which results in patchy hair loss

Net Sales are expected to increase by 14 percent Y-o-Y (up 2.7 percent Q-o-Q) to Rs 1,12,458 crore, according to Nirmal Bang.

However, in FY24 what we believe is that the government will again allow pharma companies to take price increases anywhere in the range of 12% to 13% on the NLEM drugs and the non-NLEM drugs again about up to 10% which will help the price realisation in terms of growth.

“Coming to the complex generics opportunity, Cipla and Lupin are most exposed. We like Cipla more than Lupin because at least in the near term, there are multiple assets waiting to play out. For Cipla this year, we are hoping to see generic Advair, generic Abraxane which is most likely in the price but beyond that, there will be a generic Qvar, there will be a generic Teriparatide and potentially a generic Flovent as well.”

“2023 was an overall good year. We expect a good stable year and from here, a lot of bottom up opportunities will come up in India across various sectors. If you look at the second quarter of FY23, it is proving that data point. I think there are many bottom up opportunities from here on. It is just the beginning of the growth cycle.”

"The bank has managed asset quality well throughout the epidemic, and the bank intends to aggressively extend its footprint through partnerships with fintech companies as well as physical expansion. We value the company at 12.8x FY23 EPS to arrive at the target of 161," the note said.

The NSE Nifty index was trading 100.25 points down at 18022.25

The NSE Nifty index was trading 113.95 points down at 18008.55

Indian companies have a very dominant market share given our low cost manufacturing base in India so I think on a broad basis most of the companies will see a very healthy profit recovery.

The US FDA last week listed the Halol facility in Gujarat under import alert with products manufactured at the unit now subject to refusal of admission in the US market.

Currently, the stock is trading above its mean+1*sigma levels where the brokerage expects it to witness fresh buying interest on dips. The brokerage expect it to cross its life-time highs.

BofA Securities maintained its buy rating on Sun Pharma with a target of Rs 1,000. Flattish llumya trend and the company is waiting for Winlevi Rx to pick up. Sun Pharma's global specialty revenue growth was 30% in H1FY23, this was largely aided by llumya ramp-up. Regulatory overhang continues.

Sun Pharmaceutical Industries, incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 238517.89 Crore) operating in Pharmaceuticals sector.

Citigroup maintained its buy rating on Hindustan Unilever with a target price of Rs 3050. The company announced entry into Health and well-being which is a positive sign, the brokerage said.

Clarifying the effect on the revenue and the revision of future guidance of the company, Sun Pharma stated, "We are not revising our revenue guidance for the current financial year."

The NSE Nifty index closed 48.85 points up at 18609.35

The development follows an inspection of the facility by the US Food and Drug Administration (USFDA) from April 26 to May 9, 2022.

Shares of Sun Pharmaceutical on Thursday lost up to 3.5% to hit the day's low at Rs 981.50 in morning trade after the company told stock exchanges that its Halol facility in Gujarat had been placed under 'Import Alert' by USFDA.We now wish to inform you that the Company received a communication from the USFDA stating that the facility has been listed under Import Alert," Sun Pharma said in a regulatory filing.

USFDA inspected the company’s Halol facility in Gujarat from April 26 to May 9, 2022

Sharekhan is bullish on Sun Pharmaceuticals Industries has recommended buy rating on the stock with a target price of Rs 1300 in its research report dated December 07, 2022.

Neeraj Dewan: Yes, definitely. There are still opportunities there. One such sector is the construction and infrastructure sector, where I do not think you are trading at high valuations right now. There are still stocks trading below their average trading multiples, and there is definitely a good order book.

The NSE Nifty index closed 140.3 points up at 18758.35

“There is no value in Bikaji Foods. The entire speculative activity in the market has shifted from the new generation technology stocks where people have lost a lot of money to these newly listed companies. Any long-term investor should just ignore these moves. HDFC Life seems to have value as it has the potential of giving double digit returns over the next one year. ICICI Pru Life got sold out very substantially right from Rs 620-630 odd to Rs 460 in a straight line,”